Abstract
Phase III approval trials for the currently used vaccines for COVID-19 excluded immunocompromised patients. Therefore, vaccine efficacy data in this population are only available from real-life non-interventional studies, most assessing anti-SARS-CoV-2 antibodies after vaccination.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
